A quiet but striking result came out of a Pune laboratory on 3 June 2026. Researchers at the Agharkar Research Institute (ARI) — an autonomous body of the Department of Science & Technology (DST) — described a way to switch off the genes that keep a breast-cancer tumour alive, delivering the "off-switch" through a tiny, self-destructing particle that homes in on the cancer and leaves healthy tissue largely untouched. Published in the journal Advanced Healthcare Materials, the work is a good example of where cancer medicine is heading — and it sits squarely on the NDA/CDS syllabus crossroads of biology, genetics and nanotechnology.
Cracking the code: DNA, RNA and how a tumour hijacks them
To see why "silencing a gene" matters, start with the central dogma of molecular biology, one of the most testable ideas in the science section: information in a cell flows from DNA → RNA → Protein. A gene is a stretch of DNA; it is first copied (transcribed) into a messenger molecule called mRNA; the mRNA is then read (translated) by the cell to build a protein. Proteins are the workhorses that actually do things in the body.
Cancer, at its root, is a disease of genes gone wrong. Mutations switch certain genes into overdrive, and the proteins they churn out tell the cell to divide endlessly and resist dying. If you could stop those particular proteins from ever being made, you could starve the tumour of the very signals keeping it alive. That is exactly the target the Pune team went after — the cancer's survival pathways.
The "off-switch": RNA interference
Nature already has an elegant tool for switching genes off, and discovering it earned Andrew Fire and Craig Mello the Nobel Prize in Medicine in 2006. It is called RNA interference (RNAi). The trick: introduce a small, custom-designed piece of RNA — a small interfering RNA (siRNA) — that recognises and latches onto the target mRNA, marking it for destruction. The message never reaches the protein-building machinery, so the harmful protein is simply not produced. The gene has been silenced without altering the DNA itself.
RNAi has become one of the hottest areas of medicine, especially after mRNA vaccines against COVID-19 proved that RNA can be turned into a safe, programmable drug. Gene-silencing RNAi therapies are now in use or trials for several genetic disorders and cancers.
Why you can't just inject the RNA — the nanocarrier problem
There is a catch. Naked RNA is extremely fragile. Injected into the bloodstream, it is chewed up by enzymes within minutes and cannot easily cross into cells. This is the gap that nanotechnology fills.
Nanomedicine applies materials engineered at the nanoscale (1 to 100 nanometres — billionths of a metre) to diagnosis and treatment. The Pune team built a biodegradable nanocarrier — think of it as a microscopic, dissolvable courier capsule — that does four jobs at once:
- Shields the siRNA from being broken down in the blood;
- Targets the breast-cancer cells specifically, so healthy cells are spared;
- Releases its RNA cargo once inside the tumour; and
- Dissolves harmlessly afterwards, since it is biodegradable, keeping side effects low.
That combination — a protected, targeted, self-clearing delivery system carrying a gene-silencing payload — is what the researchers call "next-generation precision nanomedicine."
What actually goes wrong in a cancer cell
It helps to know the vocabulary, because exam questions on cancer biology recur. Two broad gene types are involved. Oncogenes are genes that, when over-active or mutated, push cells to divide uncontrollably — like an accelerator stuck on. Tumour-suppressor genes (such as the famous p53) normally slow division and trigger the orderly self-destruction of faulty cells — like brakes; when they fail, the brakes are gone. Cancer typically involves accelerators jammed on and brakes cut. The cell also loses apoptosis — programmed cell death, the body's way of disposing of damaged cells. A gene-silencing therapy can, in effect, re-impose control by switching off an over-active survival/oncogene so the malignant cell can no longer ignore the signals to stop or die.
RNAi versus gene editing — don't confuse them
A common trap: RNA interference is not the same as CRISPR gene editing. RNAi silences a gene temporarily by destroying its mRNA — the DNA is untouched, and the effect is reversible. CRISPR-Cas9 (which won the 2020 Nobel Prize in Chemistry for Emmanuelle Charpentier and Jennifer Doudna) permanently edits the DNA sequence itself. Both are tools of modern genetics, but RNAi is a gene-expression silencer, while CRISPR is a genome editor. The Pune work uses the former.
A gentler kind of cancer therapy
Compare this with the chemotherapy and radiotherapy most people associate with cancer. Those work by killing all rapidly dividing cells, and because they cannot fully tell a cancer cell from a healthy one, they bring the familiar toll of side effects — nausea, hair loss, weakened immunity. The appeal of targeted gene therapy is selectivity: it goes after the specific genes driving this tumour, in this location, with far less collateral damage. This is the essence of precision (or personalised) medicine — tailoring treatment to the molecular fingerprint of a patient's disease rather than treating everyone the same way.
For India, the stakes are real: breast cancer is among the most commonly diagnosed cancers in Indian women, so safer, more effective therapies translate into a large public-health gain.
India's cancer burden and the response
Cancer is a rising non-communicable disease in India, with a large number of new cases each year and breast, cervical and oral cancers prominent. The public-health response that aspirants should know includes population-based screening for common cancers under the Ayushman Bharat – Health and Wellness Centres, treatment cover under Ayushman Bharat PM-JAY, a network of regional cancer centres, the National Programme for Prevention and Control of Non-Communicable Diseases, and institutions such as the Tata Memorial Centre and the National Cancer Institute, Jhajjar. Early detection plus better, less-toxic therapies — the niche this research targets — together determine survival outcomes.
The wider RNA-medicine moment
Gene-silencing nanomedicine is part of a global wave. Several RNAi-based drugs have already been approved abroad for genetic conditions, mRNA vaccine technology has been validated at scale, and antisense and siRNA therapeutics are advancing for cholesterol, liver and neurological disorders. The frontier challenge in all of them is the same one ARI tackled: delivery — getting fragile RNA safely to the right cells. That is why advances in nanocarriers and targeted delivery are as important as the RNA molecules themselves, and why an Indian contribution here is significant for the country's ambition to be a serious player in next-generation, RNA-based and precision medicine.
Where this fits in India's science push
ARI's result is one thread in a broader fabric of Indian life-science capability:
- ARI, Pune is a DST autonomous institute working across genetics, biodiversity and nano-bioscience.
- The Department of Biotechnology (DBT) and its agency BIRAC fund biotech innovation and startups.
- DST runs a Nano Mission dedicated to nanoscience and nanotechnology.
- The Government's BioE3 Policy (Biotechnology for Economy, Environment and Employment) aims to build a large, high-tech bio-economy and make India a hub for biomanufacturing.
Carry these into the exam hall
If a question touches this topic, the dependable points are: the central dogma (DNA → RNA → Protein); that RNA interference silences a gene by destroying its mRNA using siRNA; that RNAi won the 2006 Nobel; that nanomedicine works at 1–100 nm and uses nanocarriers to protect and target drugs; and that this approach is precision/targeted therapy, gentler than chemo/radiotherapy. A likely prelims framing: "Gene silencing in cancer therapy works by — switching off a specific gene so its disease-driving protein is not made." Or: "RNA interference was recognised with the Nobel Prize in Medicine in — 2006." In an interview, you could add the bigger picture: India is investing in RNA and nanomedicine because they enable targeted, less-toxic treatment and a self-reliant bio-economy.
One-line takeaway: Pune's ARI showed that a biodegradable nanoparticle carrying gene-silencing RNA can shut down a breast tumour's survival genes — a home-grown step toward precision cancer medicine.
Rapid revision Q&A
Q. What is the central dogma of molecular biology? The flow of genetic information: DNA → RNA → Protein.
Q. How does RNA interference silence a gene? A small RNA (siRNA) binds the gene's mRNA and triggers its destruction, so the protein is never made — without changing the DNA.
Q. RNAi won the Nobel Prize in Medicine in which year? 2006 (Andrew Fire and Craig Mello).
Q. How does RNAi differ from CRISPR-Cas9? RNAi temporarily silences gene expression (destroys mRNA); CRISPR permanently edits the DNA (CRISPR won the 2020 Nobel in Chemistry).
Q. What scale does nanomedicine operate at? The nanoscale, 1–100 nanometres.
Q. Which Pune institute (under which ministry/department) led the work? The Agharkar Research Institute (ARI), an autonomous institute of the Department of Science & Technology (DST).
Q. Why is a biodegradable nanocarrier used to deliver the RNA? To protect the fragile RNA, target the tumour, release the cargo inside cancer cells, and then dissolve safely — cutting toxicity to healthy tissue.